Suggested remit: To appraise the clinical and cost effectiveness of lenvatinib with everolimus or pembrolizumab within its marketing authorisation for untreated advanced renal cell carcinoma.
Status In progress
Process MTA
ID number 3760

Provisional Schedule

Expected publication 19 January 2023

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
23 October 2020 - 20 November 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
10 March 2020 In progress. Topic is in progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance